Select a Region

North America

Newscenter

Browsing Archive: BloodBlood | EVERSANA

Posted on 7 月 30, 20247/30/24

Predictive Modeling for Treatment Switching in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

EVERSANA

Posted on 9 月 25, 20239/25/23

PO206 Indirect Treatment Comparisons Of The Gene Therapy Etranacogene Dezaparvovec (CSL222) Vs. Extended Half-life Factor Ix Therapies For Severe Or Moderately Severe Haemophilia B

EVERSANA

Posted on 2 月 1, 20232/1/23

Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy

EVERSANA

Posted on 2 月 1, 20232/1/23

Systematic literature review of evidence in amyloid light-chain amyloidosis

EVERSANA

Posted on 1 月 25, 20231/25/23

Health Care Resource Utilization With Asciminib And Bosutinib Among Adults With Chronic Myeloid Leukemia In Chronic Phase Previously Treated With ≥2 Tyrosine Kinase Inhibitors: Results From ASCEMBL Trial

EVERSANA

Posted on 1 月 25, 20231/25/23

Use of Cost per Responder Models for CAR-T Therapies in Relapsed or Refractory Multiple Myeloma

EVERSANA

Posted on 1 月 2, 20231/2/23

Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review

EVERSANA

Posted on 10 月 2, 202010/2/20

Budget impact analysis of treatment‐free remission in nilotinib‐treated Japanese chronic myeloid leukemia patients

Blood